All Stories

  1. Should we consider early de-escalation of maintenance dose of antiplatelet therapy post-ACS?

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, March 2019, Oxford University Press (OUP)

    Professor Claes Held

  2. When do we need clinical endpoint adjudication in clinical trials?

    Article • Upsala Journal of Medical Sciences, November 2018, Taylor & Francis

    Professor Claes Held

  3. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease

    Article • Journal of Internal Medicine, October 2017, Wiley

    Prof Ralph A Stewart, Professor Claes Held

  4. Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

    Article • Journal of the American Heart Association, October 2017, Wolters Kluwer Health

    Prof Ralph A Stewart, Professor Claes Held

  5. Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

    Article • Journal of the American Heart Association, September 2017, Wolters Kluwer Health

    Prof Ralph A Stewart, Professor Claes Held, Dr Christopher B Granger

  6. Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease

    Article • Journal of the American Heart Association, August 2017, Wolters Kluwer Health

    Prof Ralph A Stewart, Professor Claes Held

  7. Lipoprotein‐Associated Phospholipase A2Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

    Article • Journal of the American Heart Association, June 2016, Wolters Kluwer Health

    Prof Ralph A Stewart, Professor Claes Held

  8. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar

    Article • Catheterization and Cardiovascular Interventions, December 2015, Wiley

    Professor Claes Held

  9. Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

    Article • Journal of the American Heart Association, December 2015, Wolters Kluwer Health

    Professor Claes Held

  10. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

    Article • European Heart Journal, December 2014, European Society of Cardiology

    Professor Claes Held